Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China

OBJECTIVE: Six anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs), including one domestic (ensartinib) and five imported ALK-TKIs (crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib), have been recommended as first-line treatments for advanced ALK-positive NSCLC in China. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Xia, Zhou, Zhen, Zeng, Xiaohui, Peng, Liubao, Liu, Qiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533130/
https://www.ncbi.nlm.nih.gov/pubmed/36211665
http://dx.doi.org/10.3389/fpubh.2022.985834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533130/
https://www.ncbi.nlm.nih.gov/pubmed/36211665
http://dx.doi.org/10.3389/fpubh.2022.985834

Ejemplares similares